<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen KP</submitter><funding>Ministry of Science and Technology, Taiwan</funding><pagination>56</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8882273</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP</pubmed_abstract><journal>Journal of neuroinflammation</journal><pubmed_title>A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.</pubmed_title><pmcid>PMC8882273</pmcid><funding_grant_id>MOST 107-2311-B-029-002</funding_grant_id><funding_grant_id>MOST 109-2622-B-029 -001</funding_grant_id><pubmed_authors>Cheng CY</pubmed_authors><pubmed_authors>Hsu HT</pubmed_authors><pubmed_authors>Tsai FT</pubmed_authors><pubmed_authors>Yang DI</pubmed_authors><pubmed_authors>Chen KP</pubmed_authors><pubmed_authors>Ju TC</pubmed_authors><pubmed_authors>Hua KF</pubmed_authors><pubmed_authors>Lin TY</pubmed_authors></additional><is_claimable>false</is_claimable><name>A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.</name><description>&lt;h4>Background&lt;/h4>Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin (HTT) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functions of many cellular proteins and subsequently jeopardizes important cellular machineries in major types of brain cells, including neurons, astrocytes, and microglia. The NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome, which comprises NLRP3, ASC, and caspase-1, is involved in the activation of IL-1β and IL-18 and has been implicated in various biological functions. Although the existence of the NLRP3 inflammasome in the brain has been documented, the roles of the NLRP</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Feb</publication><modification>2025-04-22T03:47:26.414Z</modification><creation>2025-04-05T20:49:10.424Z</creation></dates><accession>S-EPMC8882273</accession><cross_references><pubmed>35219323</pubmed><doi>10.1186/s12974-022-02419-9</doi></cross_references></HashMap>